However, adverse effects have presented a major challenge to the implementation of anti–TGF-β therapies, likely due to the dual nature of TGF-β signaling, which can both function as a tumor suppressor in carcinoma cells and promote tumor progression in other contexts, especially in immune cells (39, 40). The gene discussed is TGFB1; the disease is carcinoma.